相似文献
1
Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients.
J Nephropathol. 2012 Oct;1(3):123-5. doi: 10.5812/nephropathol.8106. Epub 2012 Oct 1.
2
Decrease of serum paraoxonase activity in chronic renal failure.
J Am Soc Nephrol. 1998 Nov;9(11):2082-8. doi: 10.1681/ASN.V9112082.
3
Effect of continuous renal-replacement therapy on paraoxonase-1-related variables in patients with acute renal failure caused by septic shock.
Clin Biochem. 2018 Nov;61:1-6. doi: 10.1016/j.clinbiochem.2018.08.010. Epub 2018 Aug 27.
4
Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
Nephrol Dial Transplant. 2012 Jul;27(7):2866-72. doi: 10.1093/ndt/gfr753. Epub 2012 Jan 12.
5
Effect of nutritional status on human paraoxonase-1 activity in patients with chronic kidney disease.
Kidney Blood Press Res. 2012;36(1):310-9. doi: 10.1159/000343383. Epub 2012 Dec 12.
6
The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia.
Nephron. 1998 Oct;80(2):166-70. doi: 10.1159/000045161.
7
Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
Hemodial Int. 2008 Oct;12(4):471-9. doi: 10.1111/j.1542-4758.2008.00311.x.
8
Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease.
Angiology. 2018 Nov;69(10):861-870. doi: 10.1177/0003319718780041. Epub 2018 Jun 18.
9
Serum Paraoxonase Levels are Correlated with Impaired Aortic Functions in Patients with Chronic Kidney Disease.
Acta Cardiol Sin. 2016 Jan;32(1):75-80. doi: 10.6515/acs20150429a.
10
Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
J Nephrol. 2004 Nov-Dec;17(6):813-8.
引用本文的文献
1
Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease.
J Clin Med. 2019 Jul 15;8(7):1034. doi: 10.3390/jcm8071034.
2
Helicobacter pylori and Serum Magnesium Level in Hemodialysis Patients.
Jundishapur J Microbiol. 2014 Feb;7(2):e11095. doi: 10.5812/jjm.11095. Epub 2014 Feb 1.
3
Oxidative stress and the paradoxical effects of antioxidants.
J Res Med Sci. 2013 Jul;18(7):629.
4
5
Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients.
Cell J. 2014 Winter;15(4):378-80. Epub 2013 Nov 20.
6
Reply: oxytocin ameliorates cisplatin-induced nephrotoxicity in Wistar rats.
Ann Saudi Med. 2013 Sep-Oct;33(5):510-1. doi: 10.5144/0256-4947.2013.510b.
7
Commentary on: The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia.
J Res Med Sci. 2013 May;18(5):457-8.
8
Suppressive impact of anethum graveolens consumption on biochemical risk factors of atherosclerosis in hypercholesterolemic rabbits.
Int J Prev Med. 2013 Aug;4(8):889-95.
9
10
Commentary on: Is uric acid an indicator of metabolic syndrome in the first-degree relatives of patients with type 2 diabetes?
J Res Med Sci. 2013 Mar;18(3):267-8.
本文引用的文献
1
Low high-density lipoprotein cholesterol is not responsible for decreased paraoxonase activity in chronic renal failure.
Kidney Blood Press Res. 2012;35(4):265-72. doi: 10.1159/000334650. Epub 2012 Feb 23.
2
The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.
Antioxid Redox Signal. 2012 Mar 15;16(6):597-632. doi: 10.1089/ars.2010.3774. Epub 2011 Oct 18.
3
The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release.
Atherosclerosis. 2011 Dec;219(2):510-8. doi: 10.1016/j.atherosclerosis.2011.07.119. Epub 2011 Aug 4.
4
Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome.
Mol Biol Rep. 2012 Feb;39(2):937-43. doi: 10.1007/s11033-011-0819-x. Epub 2011 May 15.
5
Relationship between the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican population: a pilot study.
Genes Nutr. 2011 Nov;6(4):361-8. doi: 10.1007/s12263-011-0215-0. Epub 2011 Mar 25.
6
The three-gene paraoxonase family: physiologic roles, actions and regulation.
Atherosclerosis. 2011 Jan;214(1):20-36. doi: 10.1016/j.atherosclerosis.2010.08.076. Epub 2010 Oct 12.
7
Paraoxonase: Its antiatherogenic role in chronic renal failure.
Indian J Nephrol. 2010 Jan;20(1):9-14. doi: 10.4103/0971-4065.62088.
8
Serum paraoxonase activity and protein thiols in chronic renal failure patients.
Indian J Nephrol. 2008 Jan;18(1):13-6. doi: 10.4103/0971-4065.41282.
9
Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
Hemodial Int. 2008 Oct;12(4):471-9. doi: 10.1111/j.1542-4758.2008.00311.x.
10
Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.
Clin Chim Acta. 2007 Sep;384(1-2):105-12. doi: 10.1016/j.cca.2007.06.012. Epub 2007 Jun 23.
Zotero 插件